Clinical Trials Logo

Bladder Cancer Stage 0 clinical trials

View clinical trials related to Bladder Cancer Stage 0.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03552796 Withdrawn - Clinical trials for Recurrent Bladder Carcinoma

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Start date: August 1, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein (sEphB4-HSA), and to see how well it works in treating participants with bladder cancer that has come back or that isn't responding to bacillus Calmette-Guerin (BCG) vaccine treatment. sEphB4-HAS prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. Giving sEphB4-HSA may work better in treating participants with bladder cancer.